CD274 and neoplasm: Currently, several phase I and II clinical trials evaluating the therapeutic potential of the MNK1/2 inhibitor eFT508 with or without anti-PD-L1 therapy in various tumor types have been initiated or already completed (clinicaltrials.gov).